Related Experiment Videos
Ropinirole for restless legs syndrome: a placebo-controlled crossover trial
C H Adler1, R A Hauser, K Sethi
1Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA. cadler@mayo.edu
Neurology
|April 28, 2004
Summary
Ropinirole significantly improved restless legs syndrome (RLS) symptoms in a clinical trial. Many patients experienced symptom relief, with some achieving complete resolution.
Area of Science:
- Neurology
- Pharmacology
Background:
- Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move the legs.
- RLS significantly impacts quality of life, sleep, and daily functioning.
Purpose of the Study:
- To evaluate the efficacy and tolerability of ropinirole in treating Restless Legs Syndrome (RLS).
Main Methods:
- A double-blind, placebo-controlled, crossover study was conducted.
- Participants received ropinirole (0.5 to 6.0 mg/day) or a placebo.
- The RLS Rating Scale was used to assess symptom severity.
Main Results:
- Ropinirole treatment led to a significant reduction in RLS symptoms (p < 0.001).
- The mean RLS Rating Scale score decreased from 25 (7) with placebo to 13 (12) with ropinirole.
- Complete symptom resolution was observed in 8 out of 22 patients.
Conclusions:
- Ropinirole is an effective treatment for the symptoms of Restless Legs Syndrome.
- The medication was generally well-tolerated by study participants.
- Adverse events such as nausea and dizziness were reported.